Pediatrics - Pulmonology
Pfizer COVID-19 shot expanded to US children as young as 12.
12 May, 2021 | 08:53h | UTCPfizer COVID-19 shot expanded to US children as young as 12 – Associated Press
Counterpoint: Covid vaccines for children should not get emergency use authorization – The BMJ Opinion
Commentaries: Covid-19: FDA authorises Pfizer vaccine for children 12-15 – The BMJ AND Expert reaction to U.S. FDA authorising Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents – Science Media Centre
Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease
22 Apr, 2021 | 08:40h | UTC
Commentaries on Twitter
Early data from @RCHMelbourne show that, at 3-6 month follow-up, all 151 children with mild and asymptomatic #COVID19 had returned to their baseline health status and post-acute COVID-19 symptoms had resolved.
Letter from @Shidan_Tosif & colleagues: https://t.co/XXa0EPIgPY
— The Lancet Child & Adolescent Health (@LancetChildAdol) April 20, 2021
Given such little available data, this study from Australia on post-acute COVID-19 symptoms in children is very important
Findings are extremely reassuring
Post-acute symptoms were rare, and mild (cough 4%, fatigue 2%, cough and fatigue 1%)
Great news!https://t.co/TEJyES3Crx
— Alasdair Munro (@apsmunro) April 21, 2021
Great to see research looking at whether long Covid is a problem in children.
From this Melbourne cohort, enduring cough and fatigue are uncommon.
It hasn’t been clear to me whether borders will reopen before children are vaccinated so this is VIP https://t.co/iLXqwXJmOt
— Jin Russell (@DrJinRussell) April 21, 2021
Truly encouraging data on post-acute #COVID19 in children. Single-center in Australia. n=151.
8% post-acute symptoms – all symptomatic COVID-19.
Mild symptoms: cough 4%, fatigue 2%, both 1%. Duration: cough 3-8w; post-viral fatigue 6-8w. All solved in follow-up time 3-6 months. https://t.co/vKrEFZlw3C— Dr Pablo Guisado Vasco MD, PhD (@PabloGVasco) April 21, 2021
Characteristics and Disease Severity of US Children and Adolescents Diagnosed With COVID-19
14 Apr, 2021 | 01:59h | UTCCommentary: CDC: 1 in 3 children hospitalized with COVID-19 requires treatment in ICU – UPI AND 12% of Children with COVID Are Hospitalized: Study – WebMD
Commentary on Twitter
Of 2430 pediatric patients who were hospitalized with COVID-19, 756 (31.1%) experienced severe COVID-19. Severe disease was more common in patients with chronic conditions, in male patients, and in children aged 2-11 years vs children aged 12-18 years. https://t.co/3fmlCFsmo8
— COVID Reference (@CovidReference) April 10, 2021
Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When
7 Apr, 2021 | 01:52h | UTCCommentaries: New findings in COVID-related kids’ syndrome, Kawasaki disease – CIDRAP AND Most kids with serious inflammatory illness had mild COVID – Associated Press
[Press release – not published yet] Pfizer-BioNTech vaccine 100% effective against Covid-19 in adolescents
1 Apr, 2021 | 03:52h | UTCPress release: Pfizer-BioNTech Announce Positive Topline Results Of Pivotal Covid-19 Vaccine Study In Adolescents
Commentaries: The Pfizer-BioNTech Vaccine Is Said to Be Powerfully Protective in Adolescents – The New York Times AND Covid: Children ‘well protected by Pfizer vaccine’ – BBC AND Pfizer Says COVID-19 Vaccine Shows ‘100% Efficacy’ In Adolescents – NPR AND Pfizer says its COVID-19 vaccine protects younger teens – Associated Press AND Pfizer and BioNTech say vaccine prevents Covid-19 in adolescents – STAT
Commentaries on Twitter
Press release for BNT-Pfizer vaccine efficacy in 2,260 adolescents aged 12 to 15: 0 Covid-19 among vaccinated, 18 in placebo group. Adverse reactions similar to those in 16 to 25 year-olds (no extra data: could be quite high, so eyes on that) https://t.co/mCoLmCtpgv
— Hilda Bastian, PhD (@hildabast) March 31, 2021
This is really terrific
In trial of 2260 adolescents 12-15 year of age, Pfizer vaccine highly effective at preventing infections
18 infections in placebo group
0 infections in vaccine group
Robust antibody response
No serious side-effects
Looking forward to @US_FDA review https://t.co/VymGXOVb5E
— Ashish K. Jha, MD, MPH (@ashishkjha) March 31, 2021
CDC Guidance for schools says students can now stay 3 feet apart, rather than 6
21 Mar, 2021 | 22:07h | UTCCommentaries: CDC Says Schools Can Now Space Students 3 Feet Apart, Rather Than 6 – NPR AND CDC updates COVID school guidance, OKs 3-feet distancing – CIDRAP
Related: Cohort study: Effectiveness of three vs. six feet of physical distancing for controlling spread of COVID-19 among primary and secondary students and staff (study and commentary)
Commentaries on Twitter
CDC: Children in elementary schools don't need to be kept 6-feet apart. In a major policy revision, federal health officials said only 3 feet of distance is required between young children in classrooms https://t.co/UBvES1T6ps
— delthia ricks 🔬 (@DelthiaRicks) March 19, 2021
Very happy CDC now recommending 3 feet spacing in schools: "The change is momentous .because many schools.. operate on part-time or hybrid schedules in order to reduce class sizes. A 3-foot rule would allow many more schools to open in person, full time."https://t.co/wR88jdUBgM
— Monica Gandhi MD, MPH (@MonicaGandhi9) March 19, 2021
Clinician Guide to COVID-19 diagnostics in children
21 Mar, 2021 | 21:48h | UTCClinician guide to COVID-19 diagnostics – ADC Education & Practice
Study: Children and young people remain at low risk of COVID-19 mortality
11 Mar, 2021 | 08:28h | UTC
RCT: 5 days of high-dose amoxicillin therapy noninferior to 10 days for the treatment of pediatric community-acquired pneumonia
9 Mar, 2021 | 02:29h | UTCShort-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial – JAMA Pediatrics (free for a limited period)
Editorial: Rightsizing Treatment for Pneumonia in Children
Commentary: Five days of antibiotics fine for children with pneumonia – McMaster University
Commentary on Twitter (thread – click for more)
This is fantastic! In outpatient community acquired pneumonia (CAP) a 5 day course of amoxicillin is just as effective as a 10 day course. A small thread follow1/6https://t.co/ewceFEe4gw
— Ricardo Quinonez, MD (@QuinonezRicardo) March 8, 2021
Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children
2 Mar, 2021 | 02:11h | UTCAcute covid-19 and multisystem inflammatory syndrome in children – The BMJ
Commentary on Twitter
The most common symptoms in children with acute SARS-CoV-2 infection are fever and cough. This Clinical Update looks at the presentation of SARS-CoV-2 infection in children, transmission dynamics, and multisystem inflammatory disease @asicksamuelshttps://t.co/XrDtAhJUb9
— The BMJ (@bmj_latest) March 1, 2021
RCT: Similar outcomes with intermittent vs. continuous pulse oximetry in hospitalized infants with stabilized bronchiolitis
2 Mar, 2021 | 01:42h | UTCIntermittent vs Continuous Pulse Oximetry in Hospitalized Infants With Stabilized Bronchiolitis: A Randomized Clinical Trial – JAMA Pediatrics (link to abstract – $ for full-text)
Editorial: Should We Prioritize Deimplementation of Continuous Pulse Oximetry in Bronchiolitis Care?
Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19
26 Feb, 2021 | 08:43h | UTCCommentary: Studies help discern severe COVID from related kids’ syndrome – CIDRAP
Commentary on Twitter
In this case series using national MIS-C registry data, kids w MIS-C were younger (6-12 y), more likely to be non-Hispanic Black, & have severe CV or mucocutaneous involvement and more extreme inflammation vs kids w severe #COVID19 https://t.co/jmCCDPXLmf @BostonChildrens
— JAMA (@JAMA_current) February 25, 2021
New protocol tested SARS-CoV-2 positivity on day 9 among quarantined student contacts of confirmed cases, resulting in safe reduction in loss of instructional time
26 Feb, 2021 | 08:42h | UTCCommentary: Is the CDC 10-day COVID-19 quarantine guideline enough? – News Medical
Commentary on Twitter
In this study of a 9-day testing protocol for student contacts of confirmed #COVID19 cases in 1 Florida county, a reduction in loss of instructional time was found that was less than what would have occurred with 14-day quarantine https://t.co/YPft2oAvYk
— JAMA (@JAMA_current) February 19, 2021
Testing strategies for diagnosing tuberculosis in young children
24 Feb, 2021 | 02:05h | UTCSensitive and Feasible Specimen Collection and Testing Strategies for Diagnosing Tuberculosis in Young Children – JAMA Pediatrics (free for a limited period)
Editorial: Diagnosing Childhood Tuberculosis: A Small Step Forward (free for a limited period)
Commentary: Diagnosing Pediatric TB in the Resource-Limited Areas – Physician’s Weekly
Schools may see a burst of the common cold when they reopen, research suggests
24 Feb, 2021 | 02:51h | UTCSchools may see a burst of the common cold when they reopen, research suggests – STAT
SR: Multisystem inflammatory syndrome in children related to COVID-19
21 Feb, 2021 | 22:11h | UTC
Commentary on Twitter (thread – click for more)
Very proud to present our systematic review on the hyperinflammatory syndrome associated with SARS-CoV-2 in children #PIMS_TS #MISC, as published today in @EurJPediatrics.
We analyzed and summarized over 950 cases from more than 60 records. https://t.co/jO3te1KUIE
(1/n) pic.twitter.com/6BwEw7qFzi
— Levi Hoste (@LeviHoste) February 18, 2021
Cohort study: Factors associated with severe SARS-CoV-2 infection in children
17 Feb, 2021 | 01:38h | UTCFactors Associated With Severe SARS-CoV-2 Infection – Pediatrics
Commentary: Large study outlines risk factors for severe COVID-19 in children – 2 Minute Medicine
RCT: Delayed antibiotic prescription feasible for children with uncomplicated respiratory infections
12 Feb, 2021 | 02:02h | UTCDelayed Antibiotic Prescription for Children With Respiratory Infections: A Randomized Trial – Pediatrics (link to abstract – $ for full-text)
Commentary: Data support delayed antibiotics in kids with respiratory infections – CIDRAP
Study: New B.1.1.7 variant does not result in more severe disease in children compared to the original strain
12 Feb, 2021 | 02:23h | UTC
Commentary on Twitter
There were recent concerns and media reports that B.1.1.7 has more effects in children and young adults than the ancestral strain. Here are new data to provide reassurance that's not the case @LancetChildAdol https://t.co/85Dj4tl2qq pic.twitter.com/YmNOeOhpTB
— Eric Topol (@EricTopol) February 11, 2021
ERS guidelines for the management of children and adolescents with bronchiectasis
11 Feb, 2021 | 02:05h | UTC
RCT: Posaconazole noninferior to voriconazole for primary treatment of invasive aspergillosis
7 Feb, 2021 | 21:00h | UTCPosaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)